Actively Recruiting
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
Led by Deling Li · Updated on 2025-09-17
20
Participants Needed
1
Research Sites
77 weeks
Total Duration
On this page
Sponsors
D
Deling Li
Lead Sponsor
P
Peking Union Medical College Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.
CONDITIONS
Official Title
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be able to provide a written informed consent
- Radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection
- Adequate clinical condition with Karnofsky performance status of 70 or higher
You will not qualify if you...
- Concomitant major central nervous system disorders
- Severe hepatic or renal dysfunction
- History of severe allergy or hypersensitivity to intravenous radiographic contrast agents
- Claustrophobia preventing PET/CT or MRI examinations
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
Research Team
D
Deling Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here